2026-11-14 · 2026-11 / week-2
National Vision’s Q3 guide cut meets a two-session reaction, not a bounded short
National Vision’s Q3 guide cut meets a two-session reaction, not a bounded short
Summary: National Vision lowered its FY26 adjusted-comparable-sales midpoint by 1.5 percentage points. Q3 adjusted operating income still rose 63.6% after excluding the $4.7 million IEEPA refund, and management described a plan to accelerate store openings. EYE closed its first post-result session 2.65% above the pre-result close, then traded 5.60% lower the next morning. The 12-month reference map still fails 10/5. Reject / no trade.
| Run field | Value |
|---|---|
| Published | November 14, 2026, 00:33 Singapore time |
| Research cutoff | November 14, 2026, 00:33 Singapore time (November 13, 11:33 a.m. ET) |
| Scope | U.S.-listed short opportunities |
| Decision | Reject / no trade |
| Reference | EYE, $17.53 at 11:17 a.m. ET on Nov. 13; regular-session snapshot, about 16 minutes old at cutoff. |
Opportunity Ranking
| Rank | Candidate | Direction | Mispricing | Evidence freshness | Catalyst window | Positioning | 10/5 status | Tradeability | Main rejection risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EYE | Short | FY26 adjusted-comp midpoint fell from 4.0% to 2.5%; Q3 operating income still grew 63.6% excluding the refund, and the first two post-result sessions gave opposite signals. | Nov. 12 SEC 8-K and 10-Q; Nov. 12 call transcript; Nov. 13 11:17 a.m. ET quote. | FY26 close-out and planned 2027 store acceleration; exact next report date unverified. | Oct. 30 short interest was 16.43M shares, 21.34% of provider float and 9.02 days to cover; post-result borrow and positioning unknown. | Reject | Regular-session reference only; no live spread, depth, locate, borrow terms, or exit review. | Refund-stripped margin growth, accelerated openings, a discretionary $100M repurchase authorization, and crowded short interest leave upside open. |
| 2 | NBIS | Short | Q3 revenue rose 571%, while Q3 operating cash flow was -$273M against $7.30B of property and equipment purchases; 2027 growth and financing plans remain large. | Nov. 12 SEC 6-K; Nov. 13 market snapshot. | Capacity delivery, customer prepayments, and 2027 capex plan; timing and funding remain execution-sensitive. | Oct. 30 short interest was 22.27% of provider float and 2.22 days to cover; current borrow unknown. | Reject | At 11:13 a.m. ET, $113.37 was 11.87% below the prior close; the intraday range was $109.00-$123.97. The snapshot was 20 minutes old at cutoff; volatility and squeeze risk remain high. | $7.4B cash, $7.96B deferred revenue, rapid sales growth, and management’s financing plan leave a wide upside path. |
| 3 | EPC | Short | Q4 adjusted EPS rose to $0.78 from $0.52; FY27 guidance calls for 1%-3% organic growth, while adjusted net-debt leverage is 3.4x. | Nov. 12 issuer release; Nov. 13 market snapshot. | Execution of FY27 growth, margin, and cash-flow guidance; next filing date unverified. | ChartExchange’s latest table is Oct. 15: 11.15% of float and 9.71 days to cover; stale for this event. | Reject | $28.56 at 11:18 a.m. ET, 0.63% below the prior close; borrow and exit conditions unknown. | Positive guidance and improving Q4 margins counter the leverage and cash-flow concerns. |
| Control | SPY | Short | Broad-market comparator only; no issuer-specific short catalyst. | Nov. 13 market snapshot at 11:17:48 a.m. ET. | None identified for this screen. | ETF positioning does not supply an issuer-specific thesis. | No setup | Liquid broad-market instrument; no differentiated short mechanism. | The index move cannot explain EYE’s company-specific price path by itself. |
Selected research screen: EYE ranks first for information value, not as the best executable short.
Why this one now: The initial premarket selloff did not persist through the first regular session. EYE closed Nov. 12 at $18.57, up 2.65% from the Nov. 11 close of $18.09; by 11:17 a.m. ET on Nov. 13 it was $17.53. The Q3 call adds a new operating path: management’s stated plan to open 50-55 stores in 2027, about a year earlier than the prior plan. The plan raises both growth potential and execution demands.
What should surprise the reader: Q3 adjusted operating income was $32.4 million after removing the tariff refund, still 63.6% above the prior year. A third-party transcript records traffic down 5.6% and ticket up about 9%, with weakness concentrated in lower-value transactions. Margin quality, not the headline EPS increase, is the short’s central test.
Why This Is the Best Opportunity Right Now
EYE has the freshest primary evidence and a measurable disagreement between weaker guidance and better refund-stripped operating results. Its reported short position is material, but the settlement is stale and does not establish current borrow or forced covering. The two-session price path is informative about changing expectations; it does not reveal who bought or sold.
NBIS presents the larger capital-intensity debate. Its Q3 operating cash use and purchases are real, but revenue growth, customer advances, cash, deferred revenue, and financing options make the adverse squeeze path especially difficult to bound. EPC’s cash and leverage deserve scrutiny, but its positive FY27 guide and Q4 improvement weaken a short case. None clears the 10/5 gate.
Why This Can Move More Than 5% Soon
EYE moved 5.60% from the Nov. 12 close to the Nov. 13 11:17 a.m. quote. Its full-year guide, self-pay traffic, reinvestment of tariff refunds, and the ramp toward 50-55 planned store openings give investors observable tests. Those facts support volatility, not a forecast that the next move must be down. The prior 52-week low is only a historical reference and the high is not a ceiling.
10/5 Asymmetry Gate
The highest-probability reference case is $18.09, the Nov. 11 close before results. From $17.53, that is a 3.2% loss for a short. The thesis-best historical-low reference of $14.75 offers 15.9% gross downside, but the historical-high stress at $30.02 is a 71.2% adverse rise, with further upside possible. The top-to-bottom gross ratio is about 0.22:1. Borrow, spread, slippage, and exit costs are unquantified and would worsen the economics.
The base does not offer a 10% decline, the adverse path is far beyond 5%, and the model’s expected gross short return is negative. This is Reject before execution gaps are considered.
The Setup
National Vision is a U.S. optical retailer. Its fiscal third quarter ended October 3, 2026. The Nov. 12 8-K and 10-Q lower the full-year comp and earnings ranges while reporting positive Q3 comparable sales and higher adjusted operating income. The setup is not a distressed-balance-sheet thesis: cash was $60.0 million, debt $233.6 million, the $300 million revolver had no borrowings, and $293.3 million was available net of letters of credit.
The strongest short argument is that the lower adjusted-comp guide and weaker self-pay traffic may persist after a one-time tariff refund and favorable mix masked underlying volume pressure. The strongest long argument is that management’s mix shift, labor discipline, and store expansion are generating higher profit per transaction. The market has not yet resolved which path dominates.
The Market Price
StockAnalysis/S&P Global reports EYE’s Nov. 12 regular close at $18.57, up 2.65% from $18.09 on Nov. 11. At 11:17 a.m. ET Nov. 13, its regular-session page showed $17.53, down $1.04 or 5.60% from the Nov. 12 close, with a day range of $17.28-$18.63 and volume of 704,200. A second quote feed returned the same price but a different intraday high and volume; the map uses the StockAnalysis price and does not average its range or volume with the other feed. The session had not closed. These are reference observations, not entries.
The Nov. 12 premarket mark of $15.45 at 8:57 a.m. ET was a separate, earlier snapshot. It should not be treated as a regular-session trade or blended with the later close. No live bid, ask, spread, depth, venue quality, or exit capacity was verified. The $17.53 quote divided by the midpoint of the updated adjusted-EPS guide, $0.99, is about 17.7x. This is a non-GAAP scale check, not fair value. No timestamped analyst-consensus estimate is used.
The Mispricing
Price: EYE closed above the pre-result close on Nov. 12 and moved below it the next morning. The current quote is about 3.1% below $18.09, not a 10% decline from that reference.
Reality: FY26 adjusted-comps guidance fell from 3%-5% to 2%-3%. Q3 adjusted comps were 2.8%, while refund-stripped adjusted operating income grew 63.6%. Management says lower self-pay traffic was offset by higher-value mix and managed-care strength.
Inference: The guide cut is evidence of softer demand, but the first-session close and profit bridge argue against treating the premarket gap as proof of an earnings collapse. The second-session pullback restores some bearish pressure without establishing a durable deterioration or bounded upside.
The Positioning
ChartExchange reports 16,431,190 shares short as of the Oct. 30 settlement, 21.34% of its reported float and 9.02 days to cover. The reported short position rose 4.39% from Oct. 15. This observation predates the earnings release and both post-result sessions. Current holders, hedges, borrow fee, recall terms, and locate availability are unknown. Crowding raises squeeze risk; it does not prove forced buying.
The Catalyst
- Q3 release and call, Nov. 12: The event is complete. The issuer’s release says 2027 store growth will accelerate by one year. A StockAnalysis transcript, which is a third-party rendering rather than an issuer-filed transcript, attributes a 50-55 store plan to management and records Q3 traffic down 5.6% with ticket up about 9%. Treat the store count and traffic detail as attributed call remarks, not filed guidance.
- Nov. 13 regular session: The first post-result close was $18.57; the next session’s 11:17 a.m. quote was $17.53. The market response remains incomplete until the Nov. 13 close and cannot be converted into an entry without execution data.
- FY26 close-out: The fiscal year ends Jan. 2, 2027; an exact results date was not verified. Compare final adjusted comps, adjusted operating income of $119M-$131M, adjusted EPS of $0.95-$1.03, cash, debt, and realized repurchases with the issuer’s updated ranges.
- 2027 store expansion: Verify actual openings, required capital, sales ramp, and returns before crediting the plan. The count is management’s plan, not completed capacity or a contracted payoff.
The cheapest falsification test is the next filed quarter’s comp, traffic, and refund-stripped margin bridge, followed by reported store openings and buyback purchases. A missed guide would support a new model; it would not create a safe short by itself.
The Payoff
This is a 12-month sensitivity from the Nov. 13, 11:17 a.m. ET reference, not a fair-value estimate. Targets use the pre-result close and prior 52-week extremes because a responsible intrinsic-value range is not established from the evidence assembled. Those historical anchors are not floors or caps. Scenario probabilities are subjective, uncalibrated estimates.
Price Target and Probability Map
| Scenario | Probability | Target / level | Short return from $17.53 | Horizon | Conditions | Evidence quality |
|---|---|---|---|---|---|---|
| Top case | 25% | $14.75 | +15.9% | By Nov. 13, 2027 | Self-pay weakness deepens, adjusted comps and margin fall below the revised guide, and new-store investment precedes returns. | Low |
| Base case | 50% | $18.09 | -3.2% | By Nov. 13, 2027 | The revised guide is broadly met; mix and managed-care strength offset softer comps, leaving price near the pre-result close. | Low |
| Bottom case | 25% | $30.02 | -71.2% | By Nov. 13, 2027 | Higher-ticket growth persists, accelerated openings gain traction, repurchases occur, or crowded shorts cover. The historical high is not an upper bound. | Low |
| Invalidation | n/a | No fixed price stop | Rebuild the thesis, not an automatic exit order. | Any time | Filed results materially improve adjusted comps, self-pay traffic, cash conversion, or returns on new stores. | Medium |
| Payoff check | Result |
|---|---|
| Probability-weighted expected price | $20.24 |
| Probability-weighted gross short return | -15.4% before borrow, fees, slippage, and carrying costs |
| Current market level and timestamp | $17.53, Nov. 13, 2026, 11:17 a.m. ET; regular-session snapshot |
| Primary instrument | EYE common stock, screening only |
| 10/5 favorable base move | -3.2%; the base is adverse to a short |
| 10/5 credible adverse move | +71.2% to the historical-high stress reference; further upside is possible |
| 10/5 measurement basis | Reference-only; no verified executable entry |
| 10/5 status | Reject |
| Gross top-to-bottom reward/adverse ratio | 0.22:1; the highest-probability base has no positive reward |
| Confidence | Low; targets are historical sensitivities, borrow and exit costs are unknown |
With the base held at 50% and the remaining weight split between the historical low and high, the low-price case would need more than 42% probability just to make gross expected value positive. The model assigns 25%. Even a positive gross expectation would not repair the negative base return, adverse stress, or missing execution evidence.
The Kill Shot
The strongest counterparty case is visible in the issuer’s own quarter: after removing the $4.7M refund, adjusted operating income rose from $19.8M to $32.4M, and adjusted margin expanded 230 basis points. The company also plans to accelerate openings. The fragile short assumption is that current demand weakness will spread from lower-value self-pay transactions into the managed-care and higher-ticket cohorts before new stores earn their capital cost.
The second-session decline is not enough to validate that assumption. The most useful test is the next reported quarter’s traffic and margin bridge, with the tariff refund removed and store spending shown separately.
What Could Go Wrong
The shares can rise if managed-care strength and ticket growth persist, new stores perform, or the board uses its discretionary $100M repurchase authorization. The Nov. 2 additional tariff-refund claim is unrecognized and could add upside if recovered. The 21.34% reported short position adds squeeze risk, while current borrow and recall terms are unknown. Gaps, halts, and thin exit liquidity can create losses beyond any modeled stress. I do not have sufficient reliable data to quantify borrow or exit costs accurately.
What Would Prove This Wrong
Retire the short thesis if filed results show adjusted comps stabilizing, refund-stripped operating margins holding, cash conversion remaining sound, and the planned store openings producing acceptable returns. Actual repurchases would strengthen the countercase; the authorization alone does not. If these tests fail, rebuild valuation and the scenario map. Do not infer an executable entry from the thesis being directionally right.
Risk Audit
| Risk | Evidence | Effect on decision |
|---|---|---|
| Operating countercase | Adjusted operating income rose 63.6% excluding the refund; positive reported comps and higher-value mix remain. | A 10% base decline is not established. |
| Demand | Adjusted comps were 2.8%; FY26 midpoint fell to 2.5%; call transcript attributes 5.6% traffic decline to Q3. | Supports concern but does not establish a price target. |
| New-store capital | Management plans 50-55 openings in 2027, according to a third-party call transcript; store returns are unverified. | Growth could support upside or dilute returns. |
| Short crowding | Oct. 30 position was 21.34% of provider float and 9.02 DTC. | Squeeze risk; post-result borrow is unknown. |
| Repurchases | $100M authorization effective Nov. 9; no obligation to use it. | Potential support, not a price floor. |
| Execution | No fresh locate, borrow fee, recall terms, spread, depth, or exit capacity. | Entry stays null and execution disabled. |
| Scenario quality | Price anchors are prior close and 52-week extremes, not a valuation model. | Confidence stays low; Reject remains appropriate. |
Best Trade Strategy
No trade. Do not short EYE from this screen. The model’s base case rises from the current reference, its bottom case is far beyond the 5% adverse limit, and its weighted gross return is negative before costs. Revisit only after a filed operating update and a new model demonstrate a base decline of at least 10%, a credible adverse move no worse than 5%, at least 2:1 gross reward to adverse risk, positive expected value after costs, and verified locate, borrow, spread, depth, and exit capacity. Do not use options, leverage, margin, or market orders.
Sources
- National Vision Q3 FY2026 results, issuer release
- National Vision Q3 FY2026 Form 10-Q
- National Vision Q3 call transcript, StockAnalysis third-party rendering
- EYE Nov. 12 close and Nov. 13 regular-session quote, StockAnalysis/S&P Global
- EYE official short-interest table, Oct. 30 settlement, ChartExchange
- EYE historical price cross-check, ChartExchange
- Nebius Q3 FY2026 release, SEC 6-K Exhibit 99.1
- NBIS Nov. 13 regular-session quote, StockAnalysis/S&P Global
- NBIS official short-interest table, Oct. 30 settlement, ChartExchange
- Edgewell Q4 FY2026 results, issuer release
- EPC Nov. 13 quote, StockAnalysis/S&P Global
- EPC latest short-interest table, Oct. 15 settlement, ChartExchange
- SPY Nov. 13 market data, ChartExchange
Research Quality Scorecard
| Criterion | Score | Evidence-based reason |
|---|---|---|
| Market disagreement | 3/5 | Guide midpoints fell, refund-stripped margins rose, and the post-result price path reversed twice. |
| Evidence base | 4/5 | Fresh issuer filings and price observations; short-interest and call-transcript limitations remain. |
| Positioning and flows | 3/5 | Oct. 30 short interest is high but stale; current borrow and repositioning are unknown. |
| Catalyst path | 4/5 | FY26 close-out and 2027 store openings are observable, though next report date and returns are unverified. |
| Payoff architecture | 2/5 | Base is adverse, downside is not bounded, and the weighted reference return is negative. |
| Invalidation discipline | 4/5 | Comp, margin, cash, buyback, and store-return tests are monitorable. |
| Differentiated insight | 5/5 | Removing the refund still leaves 63.6% adjusted operating-income growth; the second-session decline does not erase it. |
| Client value | 5/5 | Shows why a guide cut and high short interest do not create a bounded short. |
| Total | 30/40 | Reject / no-trade screen; failed economics take precedence. |
Bottom Line
National Vision cut its adjusted-comps midpoint, and Q3 traffic weakness is real. Yet adjusted operating income rose 63.6% after the refund was removed, management plans to accelerate store openings, and the next-session quote is only 3.1% below the pre-result close. From $17.53, the highest-probability reference case is a 3.2% loss for a short; the historical-high stress is +71.2%. The expected gross short return is -15.4%. Reject / no trade.
AI Illustration Prompt
Create a restrained optical-retail research illustration: an earnings ledger showing “Q3 adjusted operating income $37.1M” less “$4.7M IEEPA refund” equals “$32.4M”, beside a small two-session price strip marked “Nov. 12 close $18.57” and “Nov. 13 11:17 ET $17.53”. Add a quiet inset reading “FY26 adjusted-comp midpoint 4.0% → 2.5%” and a risk note “Oct. 30 short interest 21.34%; current borrow unknown”. Use graphite, warm white, muted optical blue, and one restrained amber accent. No logos, people, arrows, or buy/sell symbols. Place a subtle readable “The Mispricing Desk” watermark on the ledger.